Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia
about
Murine models of acute leukemia: important tools in current pediatric leukemia research.SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia.CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells.Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.A PREVIOUSLY UNKNOWN UNIQUE CHALLENGE FOR INHIBITORS OF SYK ATP-BINDING SITE: ROLE OF SYK AS A CELL CYCLE CHECKPOINT REGULATORA rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignanciesConstitutive function of the Ikaros transcription factor in primary leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients.Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemiaRecombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand × Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-Resistant B-Precursor Acute Lymphoblastic Leukemia in MiceCD22ΔE12 as a molecular target for RNAi therapy.Development of Polypeptide-based Nanoparticles for Non-viral Delivery of CD22 RNA Trans-splicing Molecule as a New Precision Medicine Candidate Against B-lineage ALL.Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in MiceMolecular profiling of childhood cancer: Biomarkers and novel therapiesPre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.The potential of multi-compound nanoparticles to bypass drug resistance in cancer.
P2860
Q33606018-082D7EDB-CA17-4602-B372-CFA588014D6EQ33631405-00F99759-D284-431F-BB54-0C0C8093BBC4Q34154532-9ADE3C23-8052-4F92-9487-DF26C5F5E6A5Q34625171-026A6233-E663-4ABE-A2CE-5DAC8F69E2EDQ34653474-8BD9FEE5-BC6F-4AA9-9F7B-102AB9CA3021Q34939490-61C2B31F-41A9-40AD-ABFE-5AFFD781A650Q35053686-85286845-78AB-49A1-93A8-56E3D919E9E3Q35146292-AC071A13-87CD-4E35-BA3D-294B638E1C02Q35183874-D18A3942-E6E1-44FB-B1C5-3CA58E7009A5Q35747708-AC5AD985-92F8-4FFF-90C1-61D4160EBA26Q35801180-C0E831DD-413A-4AAA-AE55-9DC92E194F7BQ35947493-B9918A6D-1D46-4F9A-81C8-C38831E3CB40Q35949248-2A62E163-2181-42CA-9FDD-CDFAAD7DCE16Q36250783-F0FBC9F5-3AE6-4A2F-A0B9-B9AFE2C19CF6Q38796456-B0ED1FAB-04CE-46C3-B829-21051C38A239Q47114290-D6F8BC89-A5A9-4D05-B3B1-47FC4833A208
P2860
Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia
@en
type
label
Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia
@en
prefLabel
Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia
@en
P2093
P2860
P50
P1433
P1476
Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia
@en
P2093
Anoush Shahidzadeh
Ibrahim Ozercan
Ingrid Cely
Jianjun Cheng
Kazim Sahin
Sanjive Qazi
P2860
P304
P356
10.1182/BLOOD-2012-11-470633
P407
P577
2013-04-08T00:00:00Z